User Profile
Corporate
Careers
FAQ
Blog
Pricing
Social
General Modals
Advanced Modals
Search
Wizards
Pfizer Addressing Multiple Myeloma Gaps in Care for Patients in Latin America
About International Myeloma Foundation
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest global organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure through our four pillars: Research, Education, Support, and Advocacy. Click here to know more about IMF: Multiple Myeloma Information | International Myeloma Foundation
About Pfizer Global Medical Grants & Partnerships
Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMGP competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an Expert Review Panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP. For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
About the Visiting Professorship (VP) Program
The intent of this RFP is to provide financial support to organizations to host and coordinate a medical education program at their organization, to be led by two international Visiting Professors with expertise matched to the organization’s unmet educational needs surrounding the management of Multiple Myeloma. Healthcare practitioners, researchers and patients will benefit from the knowledge and on-site presence of distinguished medical experts who might otherwise be inaccessible. The goals of this program are to provide meaningful practice-based educational experiences for oncology-care teams in Latin America, building capacity in Latin American cancer medicine by identifying gaps in patient care and assisting with solutions, and building global collaborations between Latin American and Western Multiple Myeloma care professionals.
Requirements
Date RFP Issued: November 14, 2024
Clinical Area: Oncology - Hematologic - Multiple Myeloma
Area of Interest for this RFP: The intent of this Visiting Professor program is to improve patient care for Multiple Myeloma patients in Latin America by sharing advanced medical expertise, build capacity in Latin American cancer medicine by identifying unresolved gaps in patient care, and bringing solutions and building global collaborations between Latin American and Western Multiple Myeloma care professionals. Application proposals from Organizations interested in hosting this program must include but not limited to the following information:
• Description of Organization’s mission, vision, impact, and reach. This includes statistics and descriptions of the following:
• Mission and Vision.
• Numbers of hospitals and clinics in organization; regional reach and coverage.
• Numbers of patients served and patient visits.
• Numbers of hospital staff, including all employees, clinical faculty, registered nurses, medical residents and fellows, medical students, and academic faculty and students.
• Prevention, screening, diagnosis, and treatment services, certifications and specialties.
• Clinical trials experience
• Educational platforms and programs.
• Any innovation or research breakthroughs.
• Description of the Organization’s care gaps, unmet needs, challenges, and questions surrounding the management of patients with Multiple Myeloma, for which a Visiting Professor could provide education or support. Relevant clinical information for the development of the program may include but is not limited to:
• Training needs of the healthcare team including physicians, nurses, and other allied health professionals.
• Cancer care disparities that can be impacted with this program.
• MM diagnosis and referral to appropriate specialist
• Treatment landscape and emerging therapies (e.g. CAR-Ts, Bispecific antibodies, immunotherapies and other novel agents)
• Therapy management and patient monitoring
• Agenda for a two-day medical education program that should include but is not limited to:
• Example agenda for meetings during two-day program including a combination of lectures, patient case reviews, informal discussions, and other meaningful interactions with the local care team that would be facilitated. This Program is expected to be held in English due to the International Visiting Professors but can have simultaneous translation to Spanish or Portuguese if needed (costs can be reflected in the operational budget).
• Expected number of health care professionals attending this Program (e.g., own site physicians, invitees from satellite hematology sites or allied healthcare institutions, etc.)
• Expected local leaders, faculty, speakers, etc.
• Budget template for all local costs that can include, meeting rooms, AV, local onsite management, local faculty fees, onsite logistics, planning and staffing, simultaneous translation, not to exceed $30,000 USD. Travel expenses and honoraria for the Visiting Professors will be covered separately by the IMF/Pfizer collaboration and should not be included in the budget.
• Expected / desired results and outline of 12-month outcome metrics for Visiting Professorship Program that will report on enduring changes that have occurred in improvements in patient care and physician education/knowledge. A 30-day report on activities and outcomes that occurred during the Visiting Professorship Program will also be required. This report can include but is not limited to details on:
• Impact on patient management and outcomes
• Impact on physician education and knowledge
• Sustainability of practice changes
• Potential replicability and dissemination
• Collaborations with other oncology sites, medical societies, academia, etc.
• Publications and/or communications plan
Target Audience: Medical hematologists should serve as Principal Investigator (PI) and Program Chair, but all other medical disciplines can be included in the Program plan, such as: nurses, pharmacists, allied Multiple Myeloma healthcare providers, and infectiology, orthopedic, emergency and intensive care, pathology and nuclear medicine MDs
Specialties
Eligibility Requirements
• Applicant (Principal Investigator; PI) must have a medical degree (MD, MBBS, or equivalent), and hold a position as Hematologist managing patients with Multiple Myeloma in the respective market.
• Principal Investigator should serve as Chair of the proposed VP two-day medical education program.
• Applicants must be from healthcare/medical organizations that provide comprehensive medical care for patients with Multiple Myeloma, located in Argentina, Brazil, Colombia, or Mexico.
• The institution and medical hosting team must be based in one of the countries listed above.
• Only institutions / organizations / associations are eligible to receive Grants, not individuals or physician-owned medical practice groups.
• Institutions applying for this grant must have proven hematology-care capacity to host this Visiting Professorship.
• The project can involve multiple departments within an institution and/or between different institutions / organizations / associations. In this case all institutions must have a relevant role and the requesting organization must have a key role in the project.
• The project/program lead must be an employee or independent contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants approved to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
Eligible Countries:
Sponsor Details
Sponsor Institute/Organizations: Pfizer
Sponsor Type:
Address: 66 Hudson Boulevard East New York, NY 10001-2192 USA
Legal & Affiliation Disclaimer
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Grant
Letter Of Intent Deadline:
Jan 19, 2025
Final Deadline:
Jan 19, 2025
Funding Amount:
$30,000
Host Details
Affiliation: Pfizer
Address: 66 Hudson Boulevard East New York, NY 10001-2192 USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.
Invite Gmail Contacts